1802222-53-2

Basic information

• Product Name: (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride
• CAS NO: 1802222-53-2
• Molecular Weight: 191.633
• Mol File: 1802222-53-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride(1802222-53-2)
• EPA Substance Registry System: (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride(1802222-53-2)

Safety Data

• Hazardous Substances Data: 1802222-53-2(Hazardous Substances Data)

Usage

General Description

The chemical (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride is a pharmaceutical intermediate used in the synthesis of various drugs. It is a hydrochloride salt form of the compound, which is a derivative of 4-fluorophenol carrying an aminoethyl substituent at the 2-position. (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride is commonly utilized in the production of medications that target specific receptors or enzymes in the body. It has a variety of potential applications in the pharmaceutical industry due to its chemical properties and ability to be modified for different therapeutic purposes.

Upstream product

• 347-54-6 5-fluoro-2-hydroxybenzaldehyde 

Downstream Products

• 1802220-02-5 repotrectinib 

Relevant articles and documents

DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF

The present invention provides a compound as represented by formula (1) or a pharmaceutically acceptable salt, a solvate, an active metabolite, apolymorph, an isotope label, an isomer or a prodrug thereof. The present invention also provides a pharmaceutical composition containing the same and the use of the compound and the pharmaceutical composition in preparation of drugs for treating tyrosine kinase-mediated diseases. The compound and the pharmaceutical composition comprising same provided by the present disclosure have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, and break through through blood-brain barrier, also have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dosage, thereby reducing treatment costs of and possible side effects to a patient. Thus, the application potential is very great.

DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF

Disclosed are bispecific compounds (degraders) that target ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat diseases and disorders characterized or mediated by aberrant ALK activity

CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.